ADVFN US – Market Content Editor

  • IonQ Shares Climb 6% After $1 Billion Equity Offering at Premium

    IonQ Shares Climb 6% After $1 Billion Equity Offering at Premium

    IonQ, Inc. (NYSE:IONQ) stock rose 6% on Monday following the announcement of a $1.0 billion equity offering priced above the company’s recent share price. The quantum computing company set the offering price at $55.49 per share, approximately 25% higher than IonQ’s closing price on July 3. The deal includes 14,165,708 common shares and pre-funded warrants…

  • Mustang Bio Shares Surge After FDA Grants Orphan Drug Status

    Mustang Bio Shares Surge After FDA Grants Orphan Drug Status

    Mustang Bio Inc (NASDAQ:MBIO) stock soared over 78% following the U.S. Food and Drug Administration’s orphan drug designation for its MB-101 therapy targeting recurrent diffuse and anaplastic astrocytoma and glioblastoma—rare and aggressive brain cancers. The designation offers Mustang Bio benefits such as clinical trial tax credits and seven years of market exclusivity upon approval. The…

  • Allegiant Shares Rise After Bloomberg Reports Blackstone’s Deal to Buy Sunseeker Resort

    Allegiant Shares Rise After Bloomberg Reports Blackstone’s Deal to Buy Sunseeker Resort

    Allegiant Travel Company (NASDAQ:ALGT) stock climbed 3.2%, while Blackstone Inc (NYSE:BX) shares inched up 0.2%, following a Bloomberg report that Blackstone has agreed to acquire Allegiant’s Sunseeker Resort for around $200 million. According to Bloomberg, the deal could be announced as soon as Monday. The purchase price represents a steep discount compared to the $720…

  • Lexeo Therapeutics Shares Climb Following FDA Breakthrough Therapy Designation

    Lexeo Therapeutics Shares Climb Following FDA Breakthrough Therapy Designation

    Lexeo Therapeutics Inc (NASDAQ:LXEO) saw its stock rise 2.3% after the U.S. Food and Drug Administration granted breakthrough therapy designation to its gene therapy candidate for Friedreich ataxia, LX2006. This designation was awarded based on interim clinical results that demonstrated significant improvements in cardiac biomarkers and functional outcomes. LX2006 was also chosen for the FDA’s…

  • ParaZero Shares Jump After Live Counter-Drone System Impresses Israeli Defense Officials

    ParaZero Shares Jump After Live Counter-Drone System Impresses Israeli Defense Officials

    Shares of ParaZero Technologies Ltd. (NASDAQ:PRZO) rose 7% after the company showcased its DefendAir Personal Net Gun System in a successful live field demonstration that captured the attention of Israeli defense authorities. The event, held in Kfar Saba, Israel, featured real-time interception exercises where the DefendAir system neutralized every drone threat presented—including passive drones that…

  • POET Technologies Stock Drops on Heavily Discounted $25 Million Offering

    POET Technologies Stock Drops on Heavily Discounted $25 Million Offering

    Shares of POET Technologies Inc. (NASDAQ:POET) slid 9.2% on Monday following news of a $25 million public offering priced well below the company’s previous closing value. The Toronto-based photonics firm announced plans to issue 5 million units at a price of $5.00 each, representing a 12% discount to Friday’s closing price on the TSX Venture…

  • Webull Shares Slide After Securing $1 Billion Equity Line with Yorkville

    Webull Shares Slide After Securing $1 Billion Equity Line with Yorkville

    Webull Corporation (NASDAQ:BULL) shares dropped 9% after the trading platform revealed a major financing deal that could result in significant share dilution over time. The company announced it has entered into a standby equity purchase agreement with Yorkville Advisors, giving Webull the option to issue up to $1 billion worth of Class A ordinary shares…

  • Jasper Therapeutics Stock Craters After Drug Lot Irregularities Disrupt Clinical Programs

    Jasper Therapeutics Stock Craters After Drug Lot Irregularities Disrupt Clinical Programs

    Jasper Therapeutics (NASDAQ:JSPR) saw its shares plummet over 43% in premarket trading on Monday after the biotech firm disclosed manufacturing problems linked to one of its drug product lots, casting uncertainty over key clinical programs. The company revealed that certain dosing groups in its ongoing chronic spontaneous urticaria trial involving the investigational antibody briquilimab may…

  • IREN Stock Climbs as Company Hits 50 EH/s Bitcoin Mining Milestone and Expands AI Capabilities

    IREN Stock Climbs as Company Hits 50 EH/s Bitcoin Mining Milestone and Expands AI Capabilities

    IREN Limited (NASDAQ:IREN) shares climbed 5% on Monday after the tech-driven infrastructure firm announced it had reached its 50 exahash per second (EH/s) Bitcoin mining goal ahead of schedule and made significant strides in expanding its AI cloud fleet. The company reported a record month for mining revenue in June, generating $65.5 million, a slight…

  • KalVista Shares Surge Following FDA Nod for First Oral Hereditary Angioedema Treatment

    KalVista Shares Surge Following FDA Nod for First Oral Hereditary Angioedema Treatment

    KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) saw its stock soar by 19% after receiving FDA approval for EKTERLY (sebetralstat)—the first oral, on-demand treatment for hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition. The green light from regulators represents a major breakthrough for HAE patients, who until now had no alternative to injectable therapies for managing…